DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors
DDR1/2 增强胃肠道间质瘤中原发性和继发性 KIT 突变体的 KIT 活化和伊马替尼耐药性
期刊:Molecular Carcinogenesis
影响因子:3
doi:10.1002/mc.23637
Anbu Liu, Shaoting Zhang, Ming Wang, Liangying Zhang, Shidong Xu, Ahmad Nasimian, Shujing Li, Sien Zhao, Xu Cao, Jinhai Tian, Yuanyuan Yu, Zhaoyang Fan, Kun Xiao, Hui Zhao, Julhash U Kazi, Lijun Ma, Jianmin Sun